Citalopram in the treatment of dysthymic disorder

  title={Citalopram in the treatment of dysthymic disorder},
  author={David J. Hellerstein and Sarai T. Batchelder and Ruben Miozzo and D Kreditor and Steven E. Hyler and Dinu P Gangure and Joy Clark},
  journal={International Clinical Psychopharmacology},
This study aimed to provide preliminary data on the tolerability and effectiveness of citalopram for patients with dysthymic disorder. Twenty-one adult subjects meeting DSM-IV criteria for dysthymic disorder were enrolled in this 12-week open-label study, of whom 15 had pure dysthymia (e.g. no major depression in the past 2 years). Citalopram was initiated at 20 mg/day, and increased to a maximum of 60 mg/day. Response was defined as 50% or greater drop in score on the Hamilton Depression… 
Escitalopram versus placebo in the treatment of dysthymic disorder
Thirty-six outpatients with Structured Clinical Interview for DSM-III-R-diagnosed dysthymic disorder were randomly assigned to double-blind escitalopram (maximum dose 20 mg/day) versus placebo for 12 weeks, finding no significant placebo–medication differences.
Paroxetine in the treatment of dysthymic disorder without co-morbidities: A double-blind, placebo-controlled, flexible-dose study.
Paroxetine is more effective than placebo in improving symptoms and quality of life in dysthymia, and is generally tolerable.
Does a History of Alcohol Use Disorder Affect Response to Antidepressant Medication in Patients With Dysthymic Disorder?
ABSTRACT Background: Research on the relationship between depression and alcohol use disorder in remission has been scarce. The authors examined whether a lifetime history of alcohol use disorder
Association of citalopram with congenital anomalies: A meta-analysis
It can be concluded that citalopram use is not associated with major birth defects, however, physicians should carefully weigh the benefits against the potential risks of citalipram use, and counsel patients accordingly.
A Systematic Review of Personality Trait Change Through Intervention
Empirical studies identified 207 studies that had tracked changes in measures of personality traits during interventions, including true experiments and prepost change designs, and found that personality traits changed the most, and patients being treated for substance use changed the least.
A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI
A comprehensive list of medications with documented effects on salivary gland function or symptoms that may assist practitioners in assessing patients who complain of dry mouth while taking medications is compiled.
HPLC determination of Escitalopram in tablet dosage forms
Purpose: A simple, specific, precise, and accurate reversed phase liquid chromatographic (RP-LC) method has been developed for the determination of Escitalopram in tablet dosage form. Methods: The
Information for Physicians and Pharmacists About Drugs That Might Cause Dry Mouth: A Study of Monographs and Published Literature
Nearly two-thirds of the most commonly prescribed medications can cause dry mouth, yet warnings about this adverse effect and its potentially serious consequences are not readily available to physicians, pharmacists, dentists or patients.


Bupropion Sustained-Release for the Treatment of Dysthymic Disorder: An Open-Label Study
The findings suggest the effectiveness and high tolerability of bupropion SR for the treatment of DD and double-blind prospective studies are needed for the comparison of buPropion SR to both placebo and other medications, assessing both initial and sustained responses to treatment.
Venlafaxine in the treatment of dysthymia: an open-label study.
Findings suggest the benefit of venlafaxine in the treatment of chronic depression and the need for more rigorous studies.
Venlafaxine in dysthymic disorder.
This study supports the treatment of dysthymic patients with venlafaxine, which has equal efficacy and greater tolerability than tricyclic antidepressants.
Dysthymic disorder: Treatment with citalopram
The purpose of this study was to determine the dose range and safety of citalopram necessary for treatment of patients with dysthymic disorder and to attempt to increase doses in order to enhance remission of patients for a subsequent treatment study using a double-blind placebo-controlled strategy.
Efficacy and tolerability of venlafaxine in the treatment of primary dysthymia.
Venlafaxine may be useful in the treatment of primary dysthymia but placebo-controlled studies are required for confirmation.
Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: effects on personality.
Subjects' Tridimensional Personality Questionnaire scores were correlated at a 0.50 level with the Social Adjustment Scale both pre- and posttreatment, suggesting that a high degree of harm avoidance may be associated with poor social functioning.
Pharmacotherapy of dysthymia: a review.
  • R. Howland
  • Psychology, Medicine
    Journal of clinical psychopharmacology
  • 1991
The findings suggest the possibility that monoamine oxidase inhibitors (MAOIs) may be superior to tricyclic antidepressants (TCAs) in the treatment of dysthymia, although this needs to be more rigorously evaluated.
A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia.
Fluoxetine subjects showed significantly greater improvement at week 8 than placebo subjects on the Hamilton depression and CGI scales, but not on the Hopkins Symptom Check-list (58-item) or the Cornell Dysthymia Rating Scale.
Pharmacological therapy of dysthymia
  • Y. Lapierre
  • Psychology, Medicine
    Acta psychiatrica Scandinavica. Supplementum
  • 1994
It is now appropriate to consider antidepressants as a clearly effective method of treating dysthymia, following a large placebo‐controlled study of moclobemide.
Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes.
Patients with a diagnosis of early-onset primary dysthymia of at least 5 years' duration without concurrent major depression were randomly assigned to 12 weeks of acute-phase therapy with sertraline, imipramine, or placebo, and pharmacotherapy was an effective treatment in terms of psychosocial functioning as well as depressive symptoms.